Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 24, 2025; 16(10): 110056
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.110056
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.110056
Charged multivesicular body protein 7 as a prognostic biomarker in colorectal cancer metastasis
Mesut Tez, Department of Surgery, University of Health Sciences, Ankara City Hospital, Ankara 06800, Türkiye
Author contributions: Tez M wrote the manuscript, and read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: The author has no conflicts of interest to declare.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mesut Tez, Professor, Department of Surgery, University of Health Sciences, Ankara City Hospital, No. 1 Bilkent Street, District of Universities, Ankara 06800, Türkiye. mesuttez@yahoo.com
Received: May 28, 2025
Revised: June 5, 2025
Accepted: July 17, 2025
Published online: October 24, 2025
Processing time: 148 Days and 22.9 Hours
Revised: June 5, 2025
Accepted: July 17, 2025
Published online: October 24, 2025
Processing time: 148 Days and 22.9 Hours
Core Tip
Core Tip: The downregulation of charged multivesicular body protein 7 in colorectal cancer (CRC) is linked to metastasis and poor prognosis, with roles in micronuclear collapse, organelle membrane contact sites, genomic stability, Wnt signaling, and tumor microenvironment modulation. Its prognostic significance across cancers highlights its potential for targeted CRC therapies.